Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease

AIDS

Volumn 16, Issue 14, 2002, Pages 1859-1866

  Valdez, Hernan ^a   Connick, Elizabeth ^a,b   Smith, Kimberly Y ^a,c   Lederman, Michael M ^a,h   Bosch, Ronald J ^a,d   Kim, Ryung S ^a,d   St Clair, Marty ^a,e   Kuritzkes, Daniel R ^a,b   Kessler, Harold ^a,c   Fox, Lawrence ^a,f   Blanchard Vargas, Michelle ^a,g   Landay, Alan ^a,c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e GLAXOSMITHKLINE   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g AIDS Clinical Trials Group Operations Center   (United States)

^h NONE   (United States)

Author keywords

Antiretroviral therapy; CD28; CD4 lymphocytes; Immune activation; Immune competence

Indexed keywords

ANTIGEN P24; ANTIRETROVIRUS AGENT; CD28 ANTIGEN; CD38 ANTIGEN; HLA DR ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANDIDA; CLINICAL ARTICLE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOCOMPETENCE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; PHENOTYPE; PRIORITY JOURNAL; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 0037183954     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200209270-00002     Document Type: Article

References (56)

1. Birx DL, Brundage J, Larson K, et al. The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of HIV-infected patients. Military Medical Consortium for Applied Retroviral Research. J Acquir Immune Defic Syndr 1993, 6:1248-1257.
2. Dolan MA, Clerici M, Blatt SP, et al. In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis 1995, 172:79-87.
3. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981, 305:1425-1431.
4. Mildvan D, Mathur U, Enlow RW, et al. Opportunistic infections and immune deficiency in homosexual men. Ann Intern Med 1982, 96:700-704.
5. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group [see comments]. Lancet 1998, 351:543-549.
6. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team [see comments]. N Engl J Med 1997, 337:725-733.
7. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators [see comments]. N Engl J Med 1998, 338:853-860.
8. Valdez H, Chowdhry TK, Asaad R, et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999. Clin Infect Dis 2001, 32:1487-1493.
9. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000, 283:381-390.
10. Al-Harthi L, Siegel J, Spritzler J, Pottage J, Agnoli M, Landay A. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS 2000, 14:761-770.
11. Kaufman GR, Zaunders JJ, Cunningham P, et al. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS 2000, 14:2643-2651.
12. Bart PA, Rizzardi GP, Tambussi G, et al. Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy. AIDS 2000, 14:1887-1897.
13. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease [see comments]. Science 1997, 277:112-116.
14. Connick E, Lederman MM, Kotzin BL, et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis 2000, 181:358-363.
15. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998, 178:70-79.
16. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease [see comments]. Lancet 1998, 351:1682-1686.
17. Mezzaroma I, Carlesimo M, Pinter E, et al. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. AIDS 1999, 13:1187-1193.
18. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation [see comments]. Nature Med 1998, 4:208-214.
19. Badley AD, Dockrell DH, Algeciras A, et al. In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest 1998, 102:79-87.
20. Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999, 103:1391-1398.
21. Dam Nielsen S, Kjaer Ersboll A, Mathiesen L, Nielsen JO, Hansen JE. Highly active antiretroviral therapy normalizes the function of progenitor cells in human immunodeficiency virus-infected patients. J Infect Dis 1998, 178:1299-1305.
22. Isgro A, Mezzaroma I, Aiuti A, et al. Recovery of hematopoietic activity in bone marrow from human immunodeficiency virus type 1-infected patients during highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2000, 16:1471-1479.
23. Huang SS, Barbour AD, Deeks SG, et al. Reversal of human immunodeficiency virus type 1-associated hematosuppression by effective antiretroviral therapy. Clin Infect Dis 2000, 30:504-510.
24. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection [see comments]. Nature 1998, 396:690-695.
25. Zhang L, Lewin SR, Markowitz M, et al. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J Exp Med 1999, 190: 725-732.
26. Gulick RM, Mellors JW, Havlir D, et al. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med 2000, 133:35-39.
27. Pakker NG, Kroon ED, Roos MT, et al. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. AIDS 1999, 13:203-212.
28. Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999, 13:669-676.
29. Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS 2000, 14:959-969.
30. Notermans DW, Pakker NG, Hamann D, et al. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults. J Infect Dis 1999, 180:1050-1056.
31. Angel JB, Parato KG, Kumar A, et al. Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression. J Infect Dis 2001, 183:546-554.
32. Tarwater PM, Margolick JB, Jin J, et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 27:168-175.
33. ACTG. AIDS Clinical Trials Group Consensus Methodologies. Bethesda: National Institutes of Health; 1997.
34. Valdez H, Smith KY, Landay A, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS 2000, 14:11-21.
35. Mackall CL, Stein D, Fleisher TA, et al. Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults. Blood 2000, 96:754-762.
36. Nordoy T, Kolstad A, Endresen P, et al. Persistent changes in the immune system 4-10 years after ABMT. Bone Marrow Transplant 1999, 24:873-878.
37. Kitchen SG, Killian S, Giorgi JV, Zack JA. Functional reconstitution of thymopoiesis after human immunodeficiency virus infection. J Virol 2000, 74:2943-2948.
38. Teixeira L, Valdez H, McCune JM, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001, 15:1749-1756.
39. Roux E, Dumont-Girard F, Starobinski M, et al. Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity. Blood 2000, 96:2299-2303.
40. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995, 332:143-149.
41. Steinmann GG, Klaus B, Muller-Hermelink HK. The involution of the ageing human thymic epithelium is independent of puberty. A morphometric study. Scand J Immunol 1985, 22:563-575.
42. Haynes BF, Hale LP. The human thymus. A chimeric organ comprised of central and peripheral lymphoid components. Immunol Res 1998, 18:175-192.
43. Marandin A, Katz A, Oksenhendler E, et al. Loss of primitive hematopoietic progenitors in patients with human immunodeficiency virus infection. Blood 1996, 88:4568-4578.
44. Paiva DD, Morais JC, Pilotto J, Veloso V, Duarte F, Lenzi HL. Spectrum of morphologic changes of lymph nodes in HIV infection. Mem Inst Oswaldo Cruz 1996, 91:371-379.
45. Haynes BF, Hale LP, Weinhold KJ, et al. Analysis of the adult thymus in reconstitution of T lymphocytes in HIV-1 infection, J Clin Invest 1999, 103:921.
46. Orenstein JM, Feinberg M, Yoder C, et al. Lymph node architecture preceding and following 6 months of potent antiviral therapy: follicular hyperplasia persists in parallel with p24 antigen restoration after involution and CD4 cell depletion in an AIDS patient. AIDS 1999, 13:2219-2229.
47. Pilcher CD, Miller WC, Beatty ZA, Eton JJ. Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virologic relapse on antiretroviral therapy. AIDS 1999, 13:1337-1342.
48. Sharkey ME, Teo I, Greenough T, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy. Nature Med 2000, 6:76-81.
49. Dornadula G, Nunnari G, Vanella M, et al. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. J Infect Dis 2001, 183:1682-1687.
50. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999, 179:859-870.
51. Fahey JL, Taylor JM, Manna B, et al. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS 1998, 12:1581-1590.
52. Haffar OK, Smithgall MD, Wong JG, Bradshaw J, Linsley PS. Human immunodeficiency virus type 1 infection of CD4+ T cells down- regulates the expression of CD28: effect on T cell activation and cytokine production. Clin Immunol Immunopathol 1995, 77:262-270.
53. Lange C, Valdez H, Medvik K, Asaad R, Lederman M. CD4+ T-lymphocyte nadir and the effect of HAART on T-lymphocyte restoration and function in HIV infection. Presented at the Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001.
54. Blankson JN, Gallant JE, Siliciano RF. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution. J Infect Dis 2001, 183:657-661.
55. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HW-1-specific CD4+ T cell responses associated with control of viremia [see comments]. Science 1997, 278:1447-1450.
56. Storek J, Gooley T, Witherspoon RP, Sullivan KM, Storb R. Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with Iow CD4 T cell counts. Am J Hematol 1997, 54:131-138a